Weekly Growth Shot Approved for Turner Syndrome
Children with Turner syndrome and their families now have a once-weekly option instead of daily growth hormone injections.
Updated on Nov. 20, 2026 in Diabetes

The U.S. Food and Drug Administration approved Novo Nordisk's once-weekly growth hormone treatment, Sogroya, for children aged 2.5 years and older with growth failure associated with Turner syndrome, the company announced on Friday. The approval gives families an alternative to daily growth hormone injections for this group of children.
Why it matters
For children with Turner syndrome, growth hormone therapy has traditionally meant daily injections over many years, so a once-weekly option could meaningfully reduce treatment burden. The approval expands Sogroya's existing uses, which already include growth hormone deficiency and Noonan syndrome.
The approval rests on the Phase 3 Real8 trial, which enrolled 105 children with Turner syndrome and compared once-weekly Sogroya with daily growth hormone injections over 52 weeks. Children on the weekly treatment grew an average of 8.9 centimeters per year, versus 9.7 centimeters per year with daily injections, and the trial did not report outcomes beyond that 52-week period.
The players
Novo Nordisk
Danish pharmaceutical company known for its diabetes and obesity treatments and its long-acting growth hormone therapies, including Sogroya.
U.S. Food and Drug Administration
The U.S. federal agency responsible for reviewing and approving drugs, including pediatric treatments for hormone-related conditions.
The details
Sogroya is a long-acting growth hormone that is given as a single injection once a week rather than every day. In the Real8 trial, that schedule produced slightly less annual growth than daily injections, and the approved use is for children aged 2.5 years and older with growth failure linked to Turner syndrome, a condition that affects around one in 2,000 newborn females.
Timeline
The Real8 trial treatment period lasted 52 weeks, comparing once-weekly Sogroya with daily growth hormone injections.
The FDA approval was announced by Novo Nordisk on Friday, November 20, 2026.
Health Landscape
Sogroya's earlier approvals for growth hormone deficiency and Noonan syndrome established it as a long-acting option in pediatric growth treatment. Adding Turner syndrome extends that category toward a condition that affects roughly one in 2,000 newborn females, where daily injections have been the conventional route.
If your child has been diagnosed with Turner syndrome or growth failure, a once-weekly option may be worth raising with their pediatric endocrinologist as a way to reduce how many injections they need. Families should discuss with their doctor whether this alternative fits their child's situation, since growth results differed slightly from daily treatment in the trial.
The takeaway
Once-weekly growth hormone therapy now offers families of children with Turner syndrome a option with 313 injection-free days a year, though it produced slightly less annual growth than daily injections in the trial. Talk with your child's pediatric endocrinologist about whether a weekly schedule is appropriate for your child.
Further reading
For broader context on hormone-related conditions in children, explore our Diabetes coverage.





